CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024 16:05 ET
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
December 12, 2024 20:19 ET
|
CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Proposed Public Offering
December 11, 2024 06:17 ET
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024 07:00 ET
|
CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
December 02, 2024 04:42 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
November 18, 2024 10:20 ET
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc